Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Benzene-Poly-Carboxylic Acids Complex With Cis-Diammineplatinum (II) Dichloride In The Treatment Of Stage IV Breast Cancer Patients

S. Dewi, S. Larsén, V. Srimuninnimit, Yen-Shen Lu, T. Manuaba, Steen Lindkær-Jensen
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
An anti-cancer agent containing benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride (BP-C1) was developed to establish a low toxic and cost effective treatment of breast cancer. The study was aimed to investigate if BP-C1 could be given continuously without rest periods and to estimate Maximum Tolerated (MTD) and Minimum Efficient Dose (MED) in metastatic breast cancer (MBC) treatment. A non-randomized, multi- centre trial with 3-level Response Surface Pathway design was performed. Five MBC patients were included at each of the three design levels. BP-C1 was daily administrated intramuscularly during 32 days. The first five patients were given a cumulative dose of 0.64 mg/kg bodyweight. Based on the obtained results, the dose was increased /decreased for the next five patients in the next design level. The main variable was the National Cancer Institute Common Toxicity Criteria (NCI-CTC). Cumulative doses of 0.96 mg/kg or higher were defined as high-dose. One moderate and one mild increase in maximum NCI-CTC were found on 0.64 mg/kg, one mild increase occurred on 0.96 mg/kg and no changes were detected on 1.12 mg/kg. The Sum NCI-CTC increased (p=0.07) in the low-dose group, but reduced (p=0.09) in the high-dose group. In the high-dose group, 62.5% of the patients were classified as responders including one complete responder compared to 28.6% in the low-dose group. In conclusion, BP-C1 can safely be administrated continuously during 32 days. The MTD is larger than 1.12 mg/kg and MED estimated to 0.96 mg/kg.
This paper references
10.1007/0-387-33706-7_4
Dose-Finding in Oncology—Nonparametric Methods
A. Ivanova (2006)
Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.
Valentine J. Burroughs (2002)
10.1016/S0305-7372(03)00139-7
Platinum-based chemotherapy in metastatic breast cancer: current status.
M. Decatris (2004)
10.1016/0002-9343(50)90056-8
Evaluation of chemotherapeutic agents
C. Macleod (1949)
10.2307/2983350
Survival Analysis: A Practical Approach
D. Machin (1995)
Applied regression analysis and other multivariable methods, 3rd ed.
D. Kleinbaum (1998)
10.5860/choice.44-4794
Meyler's side effects of drugs : the international encyclopedia of adverse drug reactions and interactions
J. Aronson (2006)
Cisplatin and analogs
E. Reed (2001)
Survival Analysis: A Practical Approach. 2 ed
D Machin (2006)
Physicians' Cancer Chemotherapy Drug Manual Massachusetts: Jones and Bartlett
E Chu (2008)
The clinical evaluation of chemotherapeutic agents in cancer
Da Karnofsky (1949)
Common Toxicity Criteria (CTC) version 2.0. Available at: http://ctep cancer gov/protocolDevelopment/electr onic_applications/docs
10.1186/1756-9966-27-17
Temporal trends in breast cancer presentation in the third world
S. Anyanwu (2008)
10.1007/0-387-33706-7
Dose Finding in Drug Development
N. Ting (2006)
10.1002/SIM.1834
Quantile estimation following non-parametric phase I clinical trials with ordinal response.
R. Paul (2004)
Practical Statistic for Medical Research
Dg Altman (1991)
This is an open-access article,...
(2011)
Categorical Data Analysis. 2nd ed
A. Agresti (2002)
Licensee Bentham Open. This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc
© Dewi (2013)
10.1007/BF02967383
New guidelines to evaluate the response to treatment in solid tumors
P. Therasse (2000)
10.1200/JCO.1998.16.8.2659
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
M. Pegram (1998)
Platinum-containing cytostatic drugs
JK Aronson (2006)
10.1007/s00280-005-0109-1
Current status of dose-dense chemotherapy for breast cancer
A. Seidman (2005)
10.2307/3150614
Applied Regression Analysis and Other Multivariable Methods
D. Kleinbaum (1978)
Cancer Chemotherapy and Biotherapy : Principles and Practice
I. Burney (2011)
Survival Analysis: A Practical Approach. 2 nd ed
D Machin (2006)
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
R. Knox (1986)
10.1097/00001721-200203000-00012
Increased soluble intercellular adhesion molecule-1, breast cancer and the acute phase response
A. Blann (2002)
10.1007/978-3-642-04898-2_161
Categorical Data Analysis
A. Agresti (2011)
10.1111/J.1365-2125.1986.TB02953.X
Inter-subject and ethnic differences in paracetamol metabolism.
J. Critchley (1986)
Cancer Chemotherapy and Biotherapy: Principles and Practice
B. Chabner (2001)
Physicians' Cancer Chemotherapy
E Chu (2008)
Toxicity and pharmacokinetic profile of a new anticancer agent in canine mammary cancer
V Kristiansen (2012)
Licensee Bentham Open
Dewi



This paper is referenced by
10.2147/OAJCT.S139884
Randomized response surface pathway design with odd response outcomes in a Latin Square designed study
T. Holand (2017)
10.2147/BCTT.S174298
Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study
Kritiya Butthongkomvong (2019)
10.2147/OAJCT.S115168
Development of a randomized two-dimensional response surface pathway design with two interventional and one response variables
T. Holand (2016)
Efficacy and tolerability of BPC 1 in metastatic breast cancer : a Phase II , randomized , double-blind , and placebo-controlled Thai multi-center study
Kritiya Butthongkomvong (2019)
10.1111/vco.12144
Tolerability and pharmacokinetic profile of a novel benzene‐poly‐carboxylic acids complex with cis‐diammineplatinum (II) dichloride in dogs with malignant mammary tumours
V. Kristiansen (2017)
10.2147/OAJCT.S57955
Between- and within-patient n -level response surface pathway design in dose-finding studies
S. Dewi (2014)
10.2147/DDDT.S80451
Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substance
Steen Lindkær-Jensen (2015)
10.1200/JCO.2015.33.15_SUPPL.E12086
BP-C1 in treatment of patients with stage IV breast cancer: A randomized, double-blind, placebo-controlled multicenter study and additional open-label treatment phase.
S. Larsén (2015)
10.4172/2157-7552.1000168
Using Human Cancer Cell Lines as In vitro Model for Testing the Efficacyof CDBPA; a New Anticancer Drug
F. Fares (2016)
Semantic Scholar Logo Some data provided by SemanticScholar